Several reports have indicated the potential use of inhibitory drugs of SEMA3A signaling against kidney diseases, and also identified SEMA3A expression as a potential biomarker for the early detection and prognosis of AKI and the relapse of nephrotic syndromes. The gene discussed is SEMA3A; the disease is acute kidney injury.